GlassScriptPhysician profile
Sherri L Thomas
NPI 1902877749
$4,541.30
in general payments reported to CMS, 2019-2025
27 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.15 · 2020: $14.04 · 2021: $122 · 2022: $1,347 · 2023: $1,269 · 2024: $1,002 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.98 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.76 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $596.55 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $422.23 | 2022-2025 | |
| Lilly USA, LLC | $387.86 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $227.47 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $197.32 | 2022-2025 | Veozah, Myrbetriq |
| Corium, LLC | $189.90 | 2022-2023 | Azstarys |
| Exact Sciences Corporation | $173.64 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $149.91 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Currax Pharmaceuticals LLC | $147.95 | 2022-2024 | Contrave, Nexletol, Onzetra Xsail |
| Edwards Lifesciences Corporation | $121.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.18 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $106.78 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $103.53 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $92.84 | 2024-2025 | Airsupra, Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87.82 | 2023-2025 | Repatha, Otezla, Prolia |
| Phathom Pharmaceuticals, INC. | $64.62 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $59.79 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $48.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.64 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $37.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $36.41 | 2023-2024 | Crysvita |
| Dexcom, INC. | $21.83 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $20.26 | 2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $19.66 | 2023 | Rexulti |
| Boston Scientific Corporation | $14.94 | 2019 | |
| Merck Sharp & Dohme LLC | $13.79 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.